$SRDX (SurModics, Inc.)

$SRDX {{ '2016-01-11T16:02:47+0000' | timeago}} • Announcement

Medical device maker $SRDX said it has acquired NorMedix, a privately owned design and development company focused on ultra thin-walled, minimally invasive catheter technologies based in Plymouth, Minn. This acquisition strengthens $SRDX's vascular device expertise and research and development (R&D) capabilities.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$REGN {{ '2017-12-18T12:38:12+0000' | timeago}} • Announcement

$REGN and ISA Pharmaceuticals announced a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16-induced cancer, in combination with cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. $REGN and ISA will jointly conduct trials of treatment in cervical cancer and head-and-neck cancer.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$AGN {{ '2017-12-05T18:08:04+0000' | timeago}} • Announcement

Revance Therapeutics reported positive data for RT002, an injectable drug which would treat glabellar or frown lines. With positive results from the two Phase 3 trials, $AGN's rival plans to complete the third Phase 3 trial in 2H18 and file for FDA approval in 1H19, and introduce the competitive drug for Allergan's Botox in the U.S. in 2020.

$GMED {{ '2017-12-01T13:40:37+0000' | timeago}} • Announcement

$GMED, a musculoskeletal solutions company, reported positive results from its 7-year clinical trial on SECURE-C Cervical Artificial Disc in the treatment of cervical disc disease. SECURE-C, which is designed for disc reconstruction and motion preservation at the operated disc level, showed superior success rate compared to conventional therapies.

$REGN {{ '2017-11-29T15:11:06+0000' | timeago}} • Announcement

Pharma firm $REGN has joined hands with Decibel Therapeutics, a provider of hearing therapies, to develop new treatments for hearing problems. As per the terms of the deal, Regeneron will provide Decibel with access to its proprietary technologies, besides participating in the latter’s research programs through R&D funding and an equity investment.

$REGN {{ '2017-11-27T12:48:48+0000' | timeago}} • Announcement

$REGN said results from two Phase 2 studies that added the angiopoietin2 to EYLEA injection did not provide sufficient differentiation to warrant Phase 3 development. EYLEA results were consistent with the findings in previous clinical studies.

$RMD {{ '2017-11-17T16:34:01+0000' | timeago}} • Announcement

$RMD elected accomplished healthcare executive Karen Drexler to its BoD. Also, Chris Roberts is retiring after serving on $RMD's Board for more than 25 years. Drexler's appointment and Roberts' retirement both took effect following the company's annual meeting of shareholders held Nov. 16.

$MMSI {{ '2017-11-16T17:40:51+0000' | timeago}} • Announcement

$MMSI signed purchase agreement with $BDX for divestment assets in connection with its proposed acquisition of $BCR$MMSI expects the acquisition to provide incremental annual revenues of $42-48MM, and adjusted gross margins for the subject product lines of 60-70%. $MMSI expects deal to provide $0.10-0.19 in adjusted EPS accretion in FY18.

$MMSI {{ '2017-11-16T17:37:46+0000' | timeago}} • Announcement

$MMSI signed an asset purchase agreement with $BDX to buy certain assets which $BDX proposes to sell in connection with its proposed acquisition of $BCR. $MMSI proposes to buy the Aspira Pleural Effusion Drainage Kits and the Aspira Peritoneal Drainage System currently marketed by $BCR. The purchase price is $100MM.

$RMD {{ '2017-11-13T19:41:35+0000' | timeago}} • Infographic

$RMD ResMed Inc Earnings AlphaGraphic: Q1 2018 Highlights

$REGN {{ '2017-11-08T20:41:09+0000' | timeago}} • Webcast

$REGN said Sanofi reimbursement of its commercialization-related expenses, was $90MM for 3Q17. "We are tightening and lowering our FY17 guidance of Sanofi reimbursement of Regeneron commercialization-related expenses to $350-375MM from our previous guidance range of $370-400MM," the company said.

$REGN {{ '2017-11-08T15:12:08+0000' | timeago}} • Infographic

$REGN Regeneron Pharmaceuticals, Inc. Earnings AlphaGraphic: Q3 2017 Highlights

Recent Transcripts

INFU (InfuSystem Holdings, Inc.)
Friday, November 10 2017 - 4:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
GMED (Globus Medical, Inc.)
Wednesday, November 8 2017 - 10:30pm
SRDX (SurModics, Inc.)
Wednesday, November 8 2017 - 1:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, November 8 2017 - 1:30pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
TNDM (Tandem Diabetes Care, Inc.)
Thursday, October 26 2017 - 8:30pm
RMD (ResMed Inc.)
Thursday, October 26 2017 - 8:30pm
MMSI (Merit Medical Systems, Inc.)
Wednesday, October 25 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
INFU (InfuSystem Holdings, Inc.)
Wednesday, August 9 2017 - 8:30pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, August 9 2017 - 12:00pm
HAE (Haemonetics Corporation)
Monday, August 7 2017 - 12:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
SRDX (SurModics, Inc.)
Thursday, August 3 2017 - 12:30pm
GMED (Globus Medical, Inc.)
Wednesday, August 2 2017 - 9:30pm

AlphaGraphics you may like